MktsMarkets

Rallybio Corporation
NASDAQ: RLYBKey statistics
RLYB News
Stories mentioning RLYB from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 212.00 | 222.00 | 212.00 | 212.00 | 212.00 | 38.00 | 299.00 | 299.00 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 2,871 | 3,655 | 4,143 | 6,074 | 5,725 | 7,385 | 8,240 | 12,946 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 8,945 | 6,634 | 7,137 | 10,269 | 9,882 | 11,646 | 12,365 | 17,334 |
| Operating Income (Loss) | (8,733) | (6,412) | (6,925) | (10,057) | (9,670) | (11,608) | (12,066) | (17,035) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 254.00 | 0.00 | 22,479 | 118.00 | 174.00 | 183.00 | 251.00 | 143.00 |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (8,278) | (5,852) | 16,016 | (9,703) | (9,439) | (11,044) | (11,466) | (16,236) |
| Earnings Per Share (Basic) | (1.46) | (1.04) | 0.36 | (0.22) | (1.69) | (2.03) | (0.26) | (0.37) |
| Earnings Per Share (Diluted) | (1.46) | (1.04) | 0.36 | (0.22) | (1.69) | (2.03) | (0.26) | (0.37) |
| Weighted Average Shares Outstanding (Basic) | 5,689 | 5,629 | 45,059 | 44,841 | 5,598 | 5,443 | 44,593 | 44,128 |
| Weighted Average Shares Outstanding (Diluted) | 5,689 | 5,629 | 45,059 | 44,841 | 5,598 | 5,443 | 44,593 | 44,128 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About RLYB
Rallybio Corporation (NASDAQ: RLYB) is a stock listed on the Nasdaq Stock Market under the ticker symbol RLYB. It last traded at $16.38 (Oct 19, 2026, 10:16 AM ET), up 0.6% on the day. That gives Rallybio a market capitalisation of $86.5M and a price-to-earnings ratio of 1.9.
Over the past 52 weeks RLYB has traded between $3.67 and $17.57.
Revenue for the quarter ended Mar 31, 2026 was $212.0K; a net loss of $8.3M.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $212.0K | -$8.3M | -3904.7% |
| Dec 31, 2025 | $222.0K | -$5.9M | -2636.0% |
| Sep 30, 2025 | $212.0K | $16.0M | 7554.7% |
| Jun 30, 2025 | $212.0K | -$9.7M | -4576.9% |
From Rallybio’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…